VTGN vs. ACB, SLRN, CGC, TVGN, BTMD, INBX, DSGN, ESPR, NBTX, and MDWD
Should you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Aurora Cannabis (ACB), Acelyrin (SLRN), Canopy Growth (CGC), Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry.
VistaGen Therapeutics vs. Its Competitors
VistaGen Therapeutics (NASDAQ:VTGN) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.
78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 1.3% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aurora Cannabis has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aurora Cannabis had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 7 mentions for Aurora Cannabis and 6 mentions for VistaGen Therapeutics. Aurora Cannabis' average media sentiment score of 0.01 beat VistaGen Therapeutics' score of -0.02 indicating that Aurora Cannabis is being referred to more favorably in the news media.
VistaGen Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Aurora Cannabis has a net margin of 1.32% compared to VistaGen Therapeutics' net margin of -6,777.08%. Aurora Cannabis' return on equity of 0.13% beat VistaGen Therapeutics' return on equity.
Summary
Aurora Cannabis beats VistaGen Therapeutics on 12 of the 15 factors compared between the two stocks.
Get VistaGen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VistaGen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTGN) was last updated on 6/30/2025 by MarketBeat.com Staff
Free VTGN Stock Alerts